Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

FDA Approves First Genetically-Modified Cell Therapy to Treat Leukemia

Published

Author(s)

Carl Simon Jr.

Abstract

The FDA approved the first genetically-modified cell therapy for the treatment of leukemia on August 30, 2017 [1-2]. The treatment (tisagenlecleucel) is an "autologous genetically modified immunocellular therapy indicated for the treatment of pediatric and young adult patients 3 to 25 years of age with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL)" [3]. B- cell acute lymphoblastic leukemia is the most common malignancy diagnosed in children. The treatment is a chimeric antigen receptor (CAR) T-cell therapy, where the patient's T cells are genetically modified to express a CAR which targets CD19 which is expressed by B cells. For the treatment, cells are harvested from the patient via leukapheresis and shipped to a manufacturing facility where they are engineered to express the CAR against CD19. The manufacturing process takes 22 days and then the modified cells are shipped back to the hospital where they are administered to the patient. The potency test for release of manufactured batches is the measurement of interferon-γ production upon stimulation by CD19+ cells. The interim endpoint in the pivotal study showed remission in 52 of 63 patients (P < 0.001, 95% confidence interval 71% to 91%) [3]. The cost of the treatment is reported to be $475000 [2].
Citation
Biomaterials Forum

Keywords

cell therapy, regenerative medicine

Citation

Simon Jr., C. (2017), FDA Approves First Genetically-Modified Cell Therapy to Treat Leukemia, Biomaterials Forum (Accessed June 18, 2024)

Issues

If you have any questions about this publication or are having problems accessing it, please contact reflib@nist.gov.

Created February 28, 2017, Updated November 29, 2022